Clinical Study
Eye (2009) 23, 1275–1281; doi:10.1038/eye.2009.88; published online 29 May 2009
Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results
Some of the content of this paper was presented at the ISOPT Meeting, Budapest February 2008
Proprietary interest: None.
J M Monés1, L Amselem1, A Serrano1, M Garcia1 and M Hijano1
1Institut de la Màcula i de la Retina, Centro Médico Teknon, Barcelona, Spain
Correspondence: JM Monés, Institut de la Màcula i de la Retina, Centro Médico Teknon, D 116–117, Vilana 12, Barcelona 08022, Spain. Tel: +34 93 3933117; Fax: +34 93 3933017; E-mail: jmones@institutmacularetina.com
Received 1 October 2008; Accepted 14 February 2009; Published online 29 May 2009.
Abstract
Aims
To determine the efficacy and safety of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM).
Methods
Prospective, consecutive, non-randomized, interventional case series of 23 eyes of 23 patients with CNV secondary to PM treated with intravitreal ranibizumab as needed, after the first injection (PRN: Pro Re Nata). Patients were followed-up monthly with best-corrected visual acuity (BCVA), biomicroscopy, fluorescein angiography, and optical coherence tomography.
Results
There were 23 eyes of 23 patients, and the mean age was 51.08 (SD=17.40) years. One patient was lost during the follow-up. At the 12-month follow-up, the mean VA improved by 9.53 letters (P<0.05). In all, 69% of patients increased at least one line, and 34.7% increased three or more lines. There were no cases of moderate vision loss (>3 lines) or severe vision loss (>6 lines). Favourable outcomes were obtained in all subgroups. Patients received an average of 1.52 injections. No serious ocular complications were noted.
Conclusions
The 12-month results of this consecutive series of 23 patients suggests that a small number of injections of intravitreal ranibizumab may be safe and effective for both preventing and restoring visual loss in patients with CNV secondary to PM. Further studies to evaluate the safety and efficacy are justified.
Keywords:
choroidal neovascularization, neovascular membrane, pathologic myopia, ranibizumab, myopic CNV, anti-VEGF therapy
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family
Oncogene Review
PTEN signaling in brain: neuropathology and tumorigenesis
Oncogene Review
